Inhibikase Therapeutics, Inc. short interest in 2026
In 2026, Inhibikase Therapeutics, Inc.'s disclosed short interest ran from 10.11% of shares outstanding on 15 Jan 2026 to 13.27% on 15 Sep 2026, a change of +3.16 percentage points. The year's high was 21.34% on 27 Feb 2026 and its low 10.11% on 15 Jan 2026, averaging 14.40% across 17 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 47.49 days on 15 Sep 2026. Full history: Inhibikase Therapeutics, Inc..
Cite this page
By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2026 in figures
- Start of year
- 10.11% (15 Jan 2026)
- End of year
- 13.27% (15 Sep 2026)
- Change
- +3.16 pp
- High
- 21.34% (27 Feb 2026)
- Low
- 10.11% (15 Jan 2026)
- Average
- 14.40%
- Highest days to cover
- 47.49 (15 Sep 2026)
- SEC filings marked
- 6
Every report in 2026
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2026 | 10.11% | 14.69 | |
| 30 Jan 2026 | 11.76% | 17.85 | |
| 13 Feb 2026 | 14.02% | 12.48 | |
| 27 Feb 2026 | 21.34% | 4.61 | |
| 13 Mar 2026 | 21.33% | 11.91 | |
| 31 Mar 2026 | 13.07% | 8.42 | 10-K filed, results (8-K) |
| 15 Apr 2026 | 13.47% | 19.25 | |
| 30 Apr 2026 | 13.62% | 17.10 | |
| 15 May 2026 | 13.40% | 26.52 | 10-Q filed, results (8-K) |
| 29 May 2026 | 14.02% | 24.57 | |
| 15 Jun 2026 | 14.31% | 34.36 | |
| 30 Jun 2026 | 14.71% | 17.38 | |
| 15 Jul 2026 | 13.83% | 16.94 | |
| 31 Jul 2026 | 14.49% | 21.49 | |
| 14 Aug 2026 | 14.09% | 35.53 | 10-Q filed, results (8-K) |
| 31 Aug 2026 | 13.97% | 47.39 | |
| 15 Sep 2026 | 13.27% | 47.49 |
See also: Inhibikase Therapeutics, Inc.'s full history · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.